Skip to main content
. 2019 Sep 15;200(6):704–711. doi: 10.1164/rccm.201809-1755OC

Figure 2.

Figure 2.

High-dose aspirin suppresses prostaglandin E2 metabolite and increases cysteinyl leukotrienes in subjects with aspirin-exacerbated respiratory disease (AERD). Urinary eicosanoids were assessed at baseline and after 8 weeks of high-dose aspirin in subjects with AERD and aspirin-tolerant asthma (ATA). P values reflect a difference in change from baseline between the AERD and ATA groups. LTE4 = leukotriene E4 (AERD n = 40, ATA n = 13); PGD-M = prostaglandin D2 metabolite (AERD n = 43, ATA n = 15); PGE-M = prostaglandin E2 metabolite (AERD n = 43, ATA n = 15); TXB2 = thromboxane B2 (AERD n = 41, ATA n = 15). Data are expressed as means + SEM. *P < 0.05 and **P < 0.01.